Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci

[1]  S. Fuchs,et al.  Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1 , 2000, The Journal of Immunology.

[2]  G. Sieck,et al.  Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. , 1998, Journal of immunology.

[3]  D. Burton,et al.  Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. , 1997, Journal of immunology.

[4]  N. Lonberg,et al.  High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice , 1996, Nature Biotechnology.

[5]  D. Huszar,et al.  Antigen-specific human antibodies from mice comprising four distinct genetic modifications , 1994, Nature.

[6]  P. B. Breda Vriesman,et al.  Characterization of anti‐acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG) , 1993, Clinical and experimental immunology.

[7]  F. Padberg,et al.  Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. , 1992, The Journal of clinical investigation.

[8]  A. Vincent,et al.  Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis , 1992, Journal of Neuroimmunology.

[9]  F. Spaans,et al.  Single‐fiber electromyography in experimental autoimmune myasthenia gravis , 1990, Muscle & nerve.

[10]  A. Vincent,et al.  Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line , 1988, Journal of Neuroimmunology.

[11]  S. Tzartos,et al.  Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. , 1985, Journal of immunology.

[12]  P. Berman,et al.  Experimental myasthenia gravis. A murine system , 1980, The Journal of experimental medicine.

[13]  R. Ulevitch,et al.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.

[14]  S. Heinemann,et al.  Modulation of acetylcholine receptor by antibody against the receptor. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Engel,et al.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.

[16]  D. Drachman,et al.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. , 1977, Science.

[17]  S. Fuchs,et al.  Strain differences in the autoimmune response of mice to acetylcholine receptors , 1976, Nature.

[18]  J. Lindstrom,et al.  Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis , 1976, The Journal of experimental medicine.

[19]  A. Pestronk,et al.  Myasthenia gravis: passive transfer from man to mouse , 1975, Science.

[20]  J. Lindstrom,et al.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs , 1975, The Journal of experimental medicine.

[21]  C G Andrew,et al.  Serum Globulin in Myasthenia Gravis: Inhibition of α-Bungarotoxin Binding to Acetylcholine Receptors , 1974, Science.

[22]  J. Patrick,et al.  Autoimmune Response to Acetylcholine Receptor , 1973, Science.